GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Market Cap

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Market Cap : HK$15,831 Mil (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Shenzhen Hepalink Pharmaceutical Group Co's share price for the quarter that ended in Sep. 2024 was HK$4.13. Shenzhen Hepalink Pharmaceutical Group Co's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 1,467 Mil. Therefore, Shenzhen Hepalink Pharmaceutical Group Co's market cap for the quarter that ended in Sep. 2024 was HK$6,060 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly market cap increased from Mar. 2024 (HK$4,079 Mil) to Jun. 2024 (HK$4,783 Mil) and increased from Jun. 2024 (HK$4,783 Mil) to Sep. 2024 (HK$6,060 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual market cap declined from Dec. 2021 (HK$11,944 Mil) to Dec. 2022 (HK$8,011 Mil) and declined from Dec. 2022 (HK$8,011 Mil) to Dec. 2023 (HK$5,253 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shenzhen Hepalink Pharmaceutical Group Co's Enterprise Value for Today is HK$17,162 Mil.


Shenzhen Hepalink Pharmaceutical Group Co Market Cap Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Market Cap Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 17,402.18 11,943.82 8,011.46 5,252.93

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,971.91 5,252.93 4,079.09 4,783.40 6,059.95

Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Market Cap distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Market Cap falls into.



Shenzhen Hepalink Pharmaceutical Group Co Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Shenzhen Hepalink Pharmaceutical Group Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=HK$3.58*1467.3
=HK$5,253

Shenzhen Hepalink Pharmaceutical Group Co's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=HK$4.13*1467.3
=HK$6,060

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Shenzhen Hepalink Pharmaceutical Group Co Market Cap Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Hepalink Pharmaceutical Group Co Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
Executives
Hong Ze Jun 2101 Beneficial owner
Orbimed Capital Llc 2102 Investment manager
Morgan Stanley & Co. International Plc 2105 Underwriter
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Avict Global Holdings Limited 2101 Beneficial owner
Worldwide Healthcare Trust Plc 2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co Headlines

No Headlines